Stockreport

IMV Inc. Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer

IMV Inc. - Common Shares  (IMV) 
PDF First in-vivo T cell therapy to demonstrate clinical activity in hard-to-treat solid tumor79% of evaluable patients achieved disease control on target lesions; 53% exper [Read more]